Reviewer's report

Title: Does Dapagliflozin Regress Left Ventricular Hypertrophy in Patients with Type 2 Diabetes? A Prospective, Double-blind, Randomised, Placebo-Controlled Study

Version: 0 Date: 19 Jul 2017

Reviewer: Mai Tone Lønnebakken

Reviewer's report:

The manuscript is describing the rationale and design of an on-going prospective, double-blind, placebo controlled trial of the effect of Dapagliflozin, a SGLT2 inhibitor, on left ventricular (LV) hypertrophy (LVH) regression in patients with diabetes type 2 and LVH.

The rationale for the study is to evaluate if LVH regression is a potential mechanism for the observed significant reduction in cardiovascular risk detected in diabetic patients treated with SGLT2 inhibitors in the EMPA-REG trial. The study is important, the rationale well-founded and the study design suitable. The power calculation is clearly presented, the follow-up time of 1 year seems sufficient to detect clinical significant reduction in LV mass, which is the primary endpoint of the study. Reduction of LV mass is going to be detected by repeated cardiac MRI. Even though the reproducibility of the measurements is good, due to variability between repeated measurements and regression against the mean, I suggest that the definition of a significant reduction in LV mass is pre-specified in the methods. The results of the study are highly warranted.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal